Overview

Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This is a prospective, single-center phase I clinical study aimed at determining the maximum-tolerated dose and safety of Lintuzumab-Ac225 in combination with CLAG-M chemotherapy in the management of relapsed/refractory acute myeloid leukemia. This study uses a 3+3 design to estimate the maximum-tolerated dose (MTD).

Phase:

Phase 1

Details

Lead Sponsor:

Medical College of Wisconsin

Treatments:

Antibodies, Monoclonal
Cladribine
Cytarabine
Lenograstim
Lintuzumab
Mitoxantrone
Sargramostim